CRISPR Therapeutics (NasdaqGM:CRSP) reports material progress in commercializing Casgevy, the first FDA approved gene editing ...
Scientists are testing an entirely new way to fight heart disease: whether gene editing might offer a one-time fix for high ...
The idea of self-amplifying gene editing is to get cells to pass on packages of CRISPR machinery to their neighbours, boosting the effect ...
For most of his 20 years, a New Jersey man knew pain as a daily reality. Now, after a one-time CRISPR gene-editing treatment at Children's Hospital of Philadelphia, Austin Louis says he is finally ...
Dr. Rebecca Ahrens-Nicklas and Dr. Kiran Musunru crafted a bespoke treatment that has successfully corrected the genetic ...
Sales of Casgevy, a gene-edited treatment developed with CRISPR Therapeutics, more than tripled compared to the third quarter ...
CRISPR Therapeutics AG CRSP on Friday reported its fourth-quarter and full-year 2025 financial results, highlighting continued clinical progress, expanding uptake of Casgevy, and momentum across its ...
With a shared purpose, we can realize the true promise of CRISPR and improve healthcare, providing hope to more patients with ...
Explore groundbreaking gene-editing therapy for kidney disease, offering hope to those with polycystic kidney disease.
A research team has successfully demonstrated the world's first gene-editing treatment for Leber's hereditary optic ...
A sales partner offered a ray of hope that this company couldn't for itself.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results